IRCT20210612051548N4招募中1 期
The efficacy of radioimmunotherapy with 177Lu-DOTA-RITUXIMAB in refractory or relapsing follicular, mantle cell, and other indolent B-cell lymphomas
Boushehr University of Medical Sciences0 个研究点目标入组 10 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Histologically confirmed relapsed or refractory CD20-positive B-cell lymphoma
- •Age greater than 18 years
- •Life expectancy more than 3 months
- •Notpregnant or lactating women
- •Performance status of 2 or better according to the World Health Organization scale.
- •Absolute neutrophil count above1.5 × 109/L, a circulating lymphocyte count below 5 × 109/L, a platelet count above 100 · 109/L, a total bilirubin level of no more than 20 mmol/L, an alanine aminotransferase level below 2.5 times normal, and a serum creatinine clearance level above 60 mL/min.
- •Signed informed consent form
排除标准
- •Patients who had previously undergone radiation therapy to the pelvis, femora, or lumbar spine or high-dose treatment with stem cell transplantation.
研究者
相似试验
进行中（未招募）
不适用
Receptorial radiotherapy with 177Lu DOTATATE in somatostatine receptors positive tumours, a phase II study.cancer patientsMedDRA version: 14.1Level: HLGTClassification code 10014713Term: Endocrine neoplasms malignant and unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002891-18-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
进行中（未招募）
不适用
Receptor radionuclide therapy with [177Lu-DOTA]0,Tyr3-octreotate (177Lu-DOTATATE): a phase II trial. - NDcancer patientsMedDRA version: 9.1Level: LLTClassification code 10028980Term: NeoplasmEUCTR2007-005517-20-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
进行中（未招募）
不适用
Receptorial radiotherapy with 177Lu-DOTA-Tyr3-Octreotate as Maintaining Therapy in Extended Small Cell Lung Cancer (SCLC) after a first standard chemotherapy line - IRST162.02oncological patientsMedDRA version: 12.1Level: LLTClassification code 10026532Term: Malignant neoplasm of thoraxEUCTR2010-018333-21-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
招募中
1 期
Therapy with radiopharmaceutical 177Lu-DOTATOC (177Lu-edotreotide or 177Lu-octreotide) in patients with diagnosis of somatostatin receptor positive tumor: a multicenter, prospective phase 2 studyPatients must have histologically or cytologically confirmation of neuroendocrine tumors or any other tumor histotype documented as sst-positiveMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2023-000086-14-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS268
尚未招募
2 期
Endoradiotherapy with 177Lu-Trastuzumab in patients with HER2-positive breast cancerMalignant breast cancer.Malignant neoplasm of breastIRCT20210612051548N3Boushehr University of Medical Sciences15